Persist AI
Developing long-lasting drug formulations 50% faster
About Persist AI
It takes 5 years for pharma to develop long lasting drug injections for chronic diseases like cancer and diabetes. Persist uses AI-driven automation to reduce formulation development time down to 2 years, a ~50% reduction.
Company details
Funding
Total raised
$16M
Last stage
Series A
Investors
Founders
Christopher Shelner
Career program manager, first time founder. Focus has been in electronics, automation, and manufacturing. Super excited to be part of the YC batch!
LinkedIn
Karthik Raman
PhD in Bioengineering with a focus on drug delivery to the brain from the University of Utah. Over 10 years of experience across drug delivery, automation, and machine learning. Previously worked on the automation team at Zymergen.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.